Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung structural changes in chronic obstructive pulmonary diseases.

Warren Davidson1, Tony R Bai

  • 1Respiratory Division, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

Current Drug Targets. Inflammation and Allergy
|February 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Airway smooth muscle proliferation and inflammation in asthma.

Journal of applied physiology (Bethesda, Md. : 1985)·2018
Same author

Inflammation-dependent and independent airway remodelling in asthma.

Respirology (Carlton, Vic.)·2018
Same author

Distribution of airway smooth muscle remodelling in asthma: relation to airway inflammation.

Respirology (Carlton, Vic.)·2014
Same author

Formation of a stable mimic of ambient particulate matter containing viable infectious respiratory syncytial virus and its dry-deposition directly onto cell cultures.

Analytical chemistry·2012
Same author

Cryptococcus gattii pneumonia.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2012
Same author

Physical activity in chronic respiratory conditions: assessing risks for physical activity clearance and prescription.

Canadian family physician Medecin de famille canadien·2012
Same journal

Emerging targets for COPD therapy.

Current drug targets. Inflammation and allergy·2007
Same journal

Animal models of pulmonary emphysema.

Current drug targets. Inflammation and allergy·2007
Same journal

Epithelial mucus-hypersecretion and respiratory disease.

Current drug targets. Inflammation and allergy·2007
Same journal

Oxidants and COPD.

Current drug targets. Inflammation and allergy·2007
Same journal

Inflammatory mediators in chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy·2007
Same journal

Inflammatory cells and chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy·2007
See all related articles

Chronic obstructive pulmonary disease (COPD) involves structural changes in airways and lung tissue, with two main pathways leading to airflow limitation. Early COPD structural changes are more reversible and responsive to interventions.

Area of Science:

  • Pulmonary Medicine
  • Respiratory System Pathophysiology
  • Chronic Obstructive Pulmonary Disease (COPD) Research

Background:

  • COPD exhibits structural alterations in central and peripheral airways, lung parenchyma, and pulmonary vasculature.
  • Two primary pathological pathways contribute to the COPD phenotype: small airway inflammation/structural change and parenchymal changes via proteolysis/abnormal repair.
  • Genetic factors influence the variable combination of these structural changes in patients.

Purpose of the Study:

  • To elucidate the structural phenotypes of COPD.
  • To correlate structural changes with physiological manifestations and disease progression.
  • To inform therapeutic strategies by understanding disease heterogeneity.

Main Methods:

  • Review of existing literature on COPD structural pathology.

Related Experiment Videos

  • Analysis of the relationship between structural changes and pulmonary function test results.
  • Consideration of genetic influences on disease presentation.

    • Main Results:

    • COPD involves diverse structural changes across multiple lung compartments.
    • Disease progression leads to irreversible changes, such as collagen deposition.
    • Pulmonary function tests reflect lung over-inflation, airflow limitation, and gas exchange abnormalities.

    Conclusions:

    • Understanding COPD structural phenotypes is crucial for patient stratification in clinical trials.
    • Early-stage COPD structural changes are more amenable to therapeutic interventions.
    • Personalized assessment of structural phenotypes may optimize COPD treatment outcomes.